Successful phase 3 trial of drug for liver cancer
An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival. Results from the study, which included researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, were recently published online in The Lancet. The trial, funded by Bayer, included 152 sites in 21 countries....

Read more at: https://medicalxpress.com/news/2017-01-successful-phase-trial-drug-liver.html#jCp
Like
Comment
Share